Barclays Maintains Overweight on Ascendis Pharma, Raises Price Target to $341
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $329 to $341.
Last updated: 2026-11-19 04:00:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ascendis Pharma A/S (ASND) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $270.32, with a market capitalization of $17.82B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $188.08 to $282.15. This page covers its latest market performance, valuation, price trends and company information.
$17.82B | |
$269.02 | |
$272.64 | |
$267.51 | |
$271.19 | |
473.82K | |
742.92K | |
-- | |
$282.15 | |
$188.08 | |
-- | |
2026-09-30 |
Ascendis Pharma A/S (ASND) last closed at $270.32 as of 2026-11-19 00:38:00, down 0.32% ($0.87) from the previous close of $271.19.
During the latest regular trading session, ASND traded between $267.51 and $272.64, with a volume of 473.82K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Ascendis Pharma A/S (ASND) moved from $259.85 to $270.32, representing a gain of 4.03% ($10.47).
The stock traded between $252.82 and $278.56 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 881.95 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 87.4%
ASND is currently trading at $270.32, placing it 87.4% of the way from its 52-week low of $188.08 to its 52-week high of $282.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
| Employees | 1,189 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Ascendis Pharma A/S and ASND stock.
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $329 to $341.
UBS analyst Joon Lee maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $269 to $315.
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $326 to $330.
RBC Capital analyst Luca Issi reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $290 price target.
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $341 to $352.
Eligible investors can buy real shares of Ascendis Pharma A/S (ASND) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ASND, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ASND shares and USD.
ASND Shares to USD
1.00 ASND shares = 270.317 USD
Calculations are estimates based on the latest available price and are for reference only.